New-onset diabetes after renal transplantation: Diagnosis, incidence, risk factors, impact on outcomes, and novel implications

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1375-1394

  Kaposztas, Z ^a   Gyurus, E ^a   Kahan, B D ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PLACEBO; PREDNISOLONE; PREDNISONE; RAPAMYCIN; STEROID; SULFONYLUREA DERIVATIVE; TACROLIMUS;

ARTICLE; BARIATRIC SURGERY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; ETHNICITY; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; HEPATITIS C; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; NEW ONSET DIABETES AFTER TRANSPLANTATION; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK FACTOR;

EID: 79959486503     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.04.008     Document Type: Review

References (144)

1. F.G. Cosio, T.E. Pesavento, and S. Kim Patient survival after renal transplantation: IV Impact of post-transplant diabetes Kidney Int 62 2002 1440
2. A.M. Miles, N. Sumrani, and R. Horowitz Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 65 1998 380
3. B.L. Kasiske, J.J. Snyder, and D. Gilbertson Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178
4. K.A. Bodziak, and D.E. Hricik New-onset diabetes mellitus after solid organ transplantation Transpl Int 22 2009 519
5. M.K. Cavaghan, D.A. Ehrmann, and K.S. Polonsky Interactions between insulin resistance and insulin secretion in the development of glucose intolerance J Clin Invest 106 2000 329
6. G.I. Bell, and K.S. Polonsky Diabetes mellitus and genetically programmed defects in beta-cell function Nature 414 2001 788
7. V.M. Montori, A. Basu, and P.J. Erwin Posttransplantation diabetes: a systematic review of the literature Diabetes Care 25 2002 583
8. J.A. Davidson, and A. Wilkinson New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view Diabetes Care 27 2004 805
9. E. Sulanc, J.T. Lane, and S.E. Puumala New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines Transplantation 80 2005 945
10. H.M. Isoniemi, J. Ahonen, and M.J. Tikkanen Long-term consequences of different immunosuppressive regimens for renal allografts Transplantation 55 1993 494
11. N. Ahsan, C. Johnson, and T. Gonwa Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years Transplantation 72 2001 245
12. L. Vesco, M. Busson, and J. Bedrossian Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors Transplantation 61 1996 1475
13. G. Ciancio, G.W. Burke, and J.J. Gaynor A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation I. Drug interactions and rejection at one year Transplantation 77 2004 244
14. T.E. Burroughs, J. Swindle, and S. Takemoto Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients Transplantation 83 2007 1027
15. O. Johnston, C.L. Rose, and A.C. Webster Sirolimus is associated with new-onset diabetes in kidney transplant recipients J Am Soc Nephrol 19 2008 1411
16. H.A. Chakkera, W.C. Knowler, and Y. Devarapalli Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus Clin J Am Soc Nephrol 5 2010 1669
17. A. Wilkinson, J. Davidson, and F. Dotta Guidelines for the treatment and management of new-onset diabetes after transplantation Clin Transplant 19 2005 291
18. Standards of medical care in diabetes-2010 Diabetes Care 33 suppl 1 2010 S11
19. KIDGO, Chapter 15: Diabetes Mellitus Am J Transplant 9 suppl 3 2009 64
20. Diagnosis and classification of diabetes mellitus Diabetes Care 33 suppl 1 2010 S62
21. Y.S. Chien, Y.T. Chen, and C.H. Chuang Incidence and risk factors of new-onset diabetes mellitus after renal transplantation Transplant Proc 40 2008 2409
22. E. Gyurus, Z. Kaposztas, and B.D. Kahan Sirolimus therapy predisposes to new onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens Transplant Proc 2011 43 this issue
23. F.G. Cosio, T.E. Pesavento, and K. Osei Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years Kidney Int 59 2001 732
24. G. Fernández-Fresnedo, R. Escallada, and A.L. de Francisco Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients Transplant Proc 35 2003 700 (Pubitemid 36338120)
25. M. Markell Clinical impact of posttransplant diabetes mellitus Transplant Proc 33 5A suppl 2001 19S
26. F.G. Cosio, Y. Kudva, and M. van der Velde New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation Kidney Int 67 2005 2415
27. D. Ducloux, A. Kazory, and J.M. Chalopin Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study Transplantation 79 2005 438
28. D. Roth, M. Milgrom, and V. Esquenazi Posttransplant hyperglycemia Increased incidence in cyclosporine-treated renal allograft recipients Transplantation 47 1989 278
29. P.Y. Benhamou, and A. Penfornis Natural history, prognosis, and management of transplantation-induced diabetes mellitus Diabetes Metab 28 2002 166
30. S. Sezer, A. Akgul, and A. Altinoglu Posttransplant diabetes mellitus: impact of good blood glucose regulation on renal transplant recipient outcome Transplant Proc 38 2006 533
31. J.P. Boudreaux, L. McHugh, and D.M. Canafax The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients Transplantation 44 1987 376
32. E.A. Friedman, T.P. Shyh, and M.M. Beyer Posttransplant diabetes in kidney transplant recipients Am J Nephrol 5 1985 196
33. V.K. Revanur, A.G. Jardine, and D.B. Kingsmore Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation Clin Transplant 15 2001 89
34. K.S. Reddy, D. Stablein, and S. Taranto Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure Am J Kidney Dis 41 2003 464
35. N.B. Sumrani, V. Delaney, and Z.K. Ding Diabetes mellitus after renal transplantation in the cyclosporine era-an analysis of risk factors Transplantation 51 1991 343
36. E.H. Cole, O. Johnston, and C.L. Rose Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival Clin J Am Soc Nephrol 3 2008 814
37. H.T. Kuo, N. Poommipanit, and M. Sampaio Risk factors for development of new-onset diabetes mellitus in pediatric renal transplant recipients: an analysis of the OPTN/UNOS database Transplantation 89 2010 434
38. J. Pascual, C. Galeano, and A. Royuela A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation Transplantation 90 2010 343
39. G. Opelz, B. Dohler, and G. Laux Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients Am J Transplant 5 2005 720
40. B.L. Kasiske, H.A. Chakkera, and T.A. Louis A meta-analysis of immunosuppression withdrawal trials in renal transplantation J Am Soc Nephrol 11 2000 1910
41. J. Hjelmesaeth, A. Hartmann, and J. Kofstad Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age Transplantation 64 1997 979
42. M.S. Kumar, M. Heifets, and M.J. Moritz Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years Transplantation 81 2006 832
43. F. Vincenti, F.P. Schena, and S. Paraskevas A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients Am J Transplant 8 2008 307
44. L. Rostaing, D. Cantarovich, and G. Mourad Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation Transplantation 79 2005 807
45. S.R. Knight, and P.J. Morris Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk A meta-analysis Transplantation 89 2010 1
46. J. Pascual, J. Zamora, and C. Galeano Steroid avoidance or withdrawal for kidney transplant recipients Cochrane Database Syst Rev 1 2009 CD005632
47. F.L. Luan, D.E. Steffick, and A.O. Ojo new-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression Transplantation 91 2011 334
48. E.S. Woodle A randomized, double-blinded, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: five year results A.S.W.S.G. Am J Transplant 8 2008 300
49. C.L. Klein, and D.C. Brennan The tradeoff between the risks of acute rejection and new-onset diabetes after kidney transplant Am J Kidney Dis 56 2010 1026
50. M.F. Crutchlow, and R.D. Bloom Transplant-associated hyperglycemia: a new look at an old problem Clin J Am Soc Nephrol 2 2007 343
51. J.B. Redmon, L.K. Olson, and M.B. Armstrong Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells J Clin Invest 98 1996 2786
52. L. Ost, G. Tyden, and I. Fehrman Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients Transplantation 46 1988 370
53. B.D. Maes, D. Kuypers, and T. Messiaen Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors Transplantation 72 2001 1655
54. C.B. Drachenberg, D.K. Klassen, and M.R. Weir Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation Transplantation 68 1999 396
55. M. Ried, S. Gibbons, and D. Kwok Cyclosporine levels in human tissues of patients treated for one week to one year Transplant Proc 15 suppl 1 1983 2434
56. E.M. van Duijnhoven, M.H. Christiaans, and J.M. Boots Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression J Am Soc Nephrol 13 2002 213
57. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412
58. R.S. Woodward, M.A. Schnitzler, and J. Baty Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients Am J Transplant 3 2003 590
59. F. Vincenti, S. Friman, and E. Scheuermann Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus Am J Transplant 7 2007 1506
60. D. Marrero, D. Hernandez, and L.P. Tamajon Pre-transplant weight but not weight gain is associated with new-onset diabetes after transplantation: a multi-centre cohort Spanish study NDT Plus 3 suppl 2 2010 ii15
61. N. Joss, C.E. Staatz, and A.H. Thomson Predictors of new onset diabetes after renal transplantation Clin Transplant 21 2007 136
62. J. Miller, J.D. Pirsch, and M. Deierhoi FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study The FK 506 Kidney Transplant Study Group Transplant Proc 29 1997 304
63. H. Ekberg, H. Tedesco-Silva, and A. Demirbas Reduced exposure to calcineurin inhibitors in renal transplantation N Engl J Med 357 2007 2562
64. D.S. Elmer, A.B. Abdulkarim, and D. Fraga Metabolic effects of FK 506 (tacrolimus) versus cyclosporine in portally drained pancreas allografts Transplant Proc 30 1998 523
65. L. Ghisdal, N.B. Bouchta, and N. Broeders Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature Transpl Int 21 2008 146
66. F.L. Luan, H. Zhang, and D.E. Schaubel Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period Am J Transplant 8 2008 1871
67. E. Rodrigo, C. Pinera, and M.A. de Cos Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation Transpl Int 18 2005 1152
68. S. Di Paolo, A. Teutonico, and D. Leogrande Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 17 2006 2236
69. M. Pende, S.C. Kozma, and M. Jaquet Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice Nature 408 2000 994
70. C.T. Bussiere, J.R. Lakey, and A.M. Shapiro The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells Diabetologia 49 2006 2341
71. N.A. Syed, and R.L. Khandelwal Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells Mol Cell Biochem 211 2000 123
72. B. Vodenik, J. Rovira, and J.M. Campistol Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc 41 6 suppl 2009 S31
73. K. Vickers, R. Mitra, and M. Kapoor Effect of sirolimus treatment on gene expression in renal transplant patients et al World J Surg 31 2007 644
74. I. Briaud, L.M. Dickson, and M.K. Lingohr Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells J Biol Chem 280 2005 2282
75. J.M. Cruzado Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors Transplant Rev (Orlando) 22 2008 73
76. E. Zahr, R.D. Molano, and A. Pileggi Rapamycin impairs beta-cell proliferation in vivo Transplant Proc 40 2008 436
77. C.G. Groth, L. Backman, and J.M. Morales Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine Sirolimus European Renal Transplant Study Group Transplantation 67 1999 1036
78. R.W. Johnson, H. Kreis, and R. Oberbauer Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777
79. R.W. Johnson, H. Kreis, and R. Oberbauer Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777
80. M. Araki, S.M. Flechner, and H.R. Ismail Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs Transplantation 81 2006 335
81. M. Veroux, D. Corona, and G. Giuffrida New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression Transplant Proc 40 2008 1885
82. M. Veroux, D. Corona, and G. Giuffrida New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression Transplant Proc 40 2008 1885
83. B.D. Kahan Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study The Rapamune US Study Group Lancet 356 2000 194
84. B.D. Kahan Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation Transplant Proc 35 3 suppl 2003 37S
85. A. Teutonico, P.F. Schena, and S. Di Paolo Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus J Am Soc Nephrol 16 2005 3128
86. J. Romagnoli, F. Citterio, and G. Nanni Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine Transplant Proc 38 2006 1034
87. O. Johnston, C.L. Rose, and A.C. Webster Sirolimus is associated with new-onset diabetes in kidney transplant recipients J Am Soc Nephrol 19 2008 1411
88. H. Podder, S.M. Stepkowski, and K.L. Napoli Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations J Am Soc Nephrol 12 2001 1059
89. M.R. First, D.A. Gerber, and S. Hariharan Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management Transplantation 73 2002 379
90. C. Johnson, N. Ahsan, and T. Gonwa Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation Transplantation 69 2000 834
91. J.A. Bluestone, W. Liu, and J.M. Yabu The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation Am J Transplant 8 2008 2086
92. M.P. Morran, G.S. Omenn, and M. Pietropaolo Immunology and genetics of type 1 diabetes Mt Sinai J Med 75 2008 314
93. T. Brusko, and J. Bluestone Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation Eur J Immunol 38 2008 931
94. X.C. Li, and L.A. Turka An update on regulatory T cells in transplant tolerance and rejection Nat Rev Nephrol 6 2010 577
95. F.W. Vondran, K. Timrott, and J. Tross Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation Transpl Int 23 2010 514
96. W. Aasebo, K. Midtvedt, and T.G. Valderhaug Impaired glucose homeostasis in renal transplant recipients receiving basiliximab Nephrol Dial Transplant 25 2010 1289
97. F.L. Luan, E. Langewisch, and A. Ojo Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients Clin Transplant 24 2010 778
98. A. Carpentier, S.D. Mittelman, and R.N. Bergman Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes Diabetes 49 2000 399
99. J.M. Osorio, C. Ferreyra, and A. Pérez Prediabetic states, subclinical atheromatosis, and oxidative stress in renal transplant patients Transplant Proc 41 2009 2148
100. V. Bonato, R. Barni, and D. Cataldo Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients Transplant Proc 40 2008 1888
101. E. Rodrigo, G. Fernandez-Fresnedo, and R. Valero New-onset diabetes after kidney transplantation: risk factors J Am Soc Nephrol 17 12 suppl 3 2006 S291
102. K. Numakura, S. Satoh, and N. Tsuchiya Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus Transplantation 80 2005 1419
103. S. Gourishankar, G.S. Jhangri, and M. Tonelli Development of diabetes mellitus following kidney transplantation: a Canadian experience Am J Transplant 4 2004 1876
104. N.D. Bayer, P.T. Cochetti, and M.S. Anil Kumar Association of metabolic syndrome with development of new-onset diabetes after transplantation Transplantation 90 2010 861
105. A. Lindholm, M. Welsh, and C. Alton Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability Clin Pharmacol Ther 52 1992 359
106. J.F. Neylan Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine FK506 Kidney Transplant Study Group Transplantation 65 1998 515
107. S. Ossareh, S. Naseem, and M.A. Faraji Frequency and risk factors for posttransplant diabetes mellitus in Iranian renal transplant patients Transplant Proc 41 2009 2814
108. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143
109. E. Porrini, P. Delgado, and C. Bigo Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation Am J Kidney Dis 48 2006 134
110. G.A. Adeseun, M.E. Rivera, and S. Thota Metabolic syndrome and coronary artery calcification in renal transplant recipients Transplantation 86 2008 728
111. A.P. de Vries, S.J. Bakker, and W.J. van Son Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally Am J Transplant 4 2004 1675
112. H. Kishikawa, K. Nishimura, and T. Kato Prevalence of the metabolic syndrome in kidney transplantation Transplant Proc 41 2009 181
113. J. Hjelmesaeth, A. Flyvbjerg, and T. Jenssen Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy Clin J Am Soc Nephrol 1 2006 575
114. J. Hung, B.M. McQuillan, and P.L. Thompson Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity Int J Obes (Lond) 32 2008 772
115. H. Kishikawa, K. Nishimura, and T. Kato Prevalence of the metabolic syndrome in kidney transplantation Transplant Proc 41 2009 181
116. F.C. Mazali, C.A. Lalli, and G. Alves-Filho Posttransplant diabetes mellitus: incidence and risk factors Transplant Proc 40 2008 764
117. H.A. Chakkera, E.J. Weil, and J. Castro Hyperglycemia during the immediate period after kidney transplantation Clin J Am Soc Nephrol 4 2009 853
118. M.B. Parolin, F.E. Zaina, and M.V. Arajo Prevalence of new-onset diabetes mellitus in Brazilian liver transplant recipients: association with HCV infection Transplant Proc 36 2004 2776
119. Y. Kishi, Y. Sugawara, and S. Tamura New-onset diabetes mellitus after living donor liver transplantation: possible association with hepatitis C Transplant Proc 38 2006 2989
120. G.G. Vosnides Hepatitis C in renal transplantation Kidney Int 52 1997 843
121. B.J. Pereira, and A.S. Levey Hepatitis C virus infection in dialysis and renal transplantation Kidney Int 51 1997 981
122. S. Caronia, K. Taylor, and L. Pagliaro Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection Hepatology 30 1999 1059
123. R.D. Bloom, V. Rao, and F. Weng Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus J Am Soc Nephrol 13 2002 1374
124. F. Fabrizi, P. Messa, and P. Martin Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis Int J Artif Organs 31 2008 675
125. E. Jaeckel, M. Manns, and M. Von Herrath Viruses and diabetes Ann N Y Acad Sci 958 2002 7
126. J. Hjelmesaeth, S. Sagedal, and A. Hartmann Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation Diabetologia 47 2004 1550
127. R.A. Hamer, C.L. Chow, and A.C. Ong Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation Transplantation 83 2007 36
128. J. Davidson, A. Wilkinson, and J. Dantal New-onset diabetes after transplantation: 2003 International consensus guidelines Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003 Transplantation 75 10 suppl 2003 SS3
129. A. Sharif, R. Moore, and K. Baboolal Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia Transplantation 85 2008 353
130. M.A. Maggard, L.R. Shugarman, and M. Suttorp Meta-analysis: surgical treatment of obesity Ann Intern Med 142 2005 547
131. L. Sjstrm, A.K. Lindroos, M. Peltonen Swedish Obese Subjects Study Scientific Group Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery N Engl J Med 351 2004 2683
132. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement Am J Clin Nutr 55 2 suppl 1992 615S
133. K.A. Mondanlou, and K.L. Lentine Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review Transplantation 87 2009 1167
134. M.C. Takata, G.M. Campos, and R. Ciovica Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation Surg Obes Relat Dis 4 2008 159
135. S. Szomstein, R. Rojas, and R.J. Rosenthal Outcomes of laparoscopic bariatric surgery after renal transplant Obes Surg 20 2010 383
136. R.H. Arias, L. Mesa, and J.G. Posada Kidney transplantation and gastric bypass: a better control of comorbidities Obes Surg 20 2010 851
137. M. Killackey, R. Zhang, and K. Sparks Challenges of abdominal organ transplant in obesity South Med J 103 2010 532
138. A.C. Gruessner, and D.E. Sutherland Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004 Clin Transplant 19 2005 433
139. J.A. Light, and D.Y. Barhyte Simultaneous pancreas-kidney transplants in type I and type II diabetic patients with end-stage renal disease: similar 10-year outcomes Transplant Proc 37 2005 1283
140. D.E. Moller New drug targets for type 2 diabetes and the metabolic syndrome Nature 414 2001 821
141. A. Rakel, and A.D. Karelis New-onset diabetes after transplantation: risk factors and clinical impact Diabetes Metab 37 2011 1
142. G. Tharakan, T. Tan, and S. Bloom Emerging therapies in the treatment of 'diabesity': beyond GLP-1 Trends Pharmacol Sci 32 2011 8
143. G. Croasdell American Diabetes Association-70th scientific sessions-research on novel therapeutics: part 2 I Drugs 13 2010 598
144. S. Thareja, S. Aggarwal, and T.R. Bhardwaj Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus Med Res Rev 2010 Sep 2 [Epub ahead of print]